Tag Archives: access-denied

Laparoscopic surgery for bladder cancer leads to good long-term cancer control

Open radical cystectomy, or removal of the bladder though open surgery, is the treatment of choice for muscle invasive and high-risk non-muscle invasive bladder cancer; however, the surgery can lead to serious complications. Some hospitals are using minimally invasive procedures such as laparoscopic radical cystectomy, but there is little information on the effectiveness of these procedures for preventing cancer recurrence over the long term…

Life expectancy increases globally as death toll falls from major diseases

Causes of death vary widely by country, but, at the global level, drug use disorders and chronic kidney disease account for some of the largest percent increases in premature deaths since 1990. Death rates from some cancers, including pancreatic cancer and kidney cancer, also increased. …

Promising drug doubled positive effect in hormone-receptor positive breast cancer, study finds

An investigational drug discovered and being developed by Pfizer Inc., palbociclib targets a key family of proteins (CDK4/6) responsible for cell growth by preventing them from dividing. Results of the multi-year phase 2 study showed a significant increase in PFS for patients with advanced breast cancer that was estrogen receptor positive (ER+), HER2-negative (HER2-), who were given a combination of the standard anti-estrogen treatment, letrozole, and palbociclib compared to letrozole alone. “We’re essentially putting the brakes on cell proliferation and causing these tumor cells to stop growing,” said Dr. …

High-definition scopes accurately assess polyps, physicians say

The benign hyperplastic polyp appears very pale and bland on imaging. Their 522-patient study, published in the December issue of Gastrointestinal Endoscopy, found that physicians correctly evaluated whether a polyp was precancerous or benign using high-definition optical lenses during a colonoscopy…

Promising drug doubled positive effect in hormone-receptor positive breast cancer, study finds — ScienceDaily

An investigational drug discovered and being developed by Pfizer Inc., palbociclib targets a key family of proteins (CDK4/6) responsible for cell growth by preventing them from dividing. Results of the multi-year phase 2 study showed a significant increase in PFS for patients with advanced breast cancer that was estrogen receptor positive (ER+), HER2-negative (HER2-), who were given a combination of the standard anti-estrogen treatment, letrozole, and palbociclib compared to letrozole alone. …